Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Navigation/Suche

• Forscher*innen.
• Institutionen.
• Projekte.
• Publikationen.
• Partner.
• Geldgeber.
• Ausstattung.
• Knowhow.
• Forschungsfelder.

Publikationen

Suchbegriffe: TEMOZOLOMIDE, . Treffer: 23

2023

Alcaniz, J; Winkler, L; Dahlmann, M; Becker, M; Orthmann, A; Haybaeck, J; Krassnig, S; Skofler, C; Kratzsch, T; Kuhn, SA; Jödicke, A; Linnebacher, M; Fichtner, I; Walther, W; Hoffmann, J Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures.
Front Oncol. 2023; 13: 1129627 Doi: 10.3389/fonc.2023.1129627 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Brawanski, KR; Sprung, S; Freyschlag, CF; Hoeftberger, R; Ströbel, T; Haybaeck, J; Thomé, C; Manzl, C; Birkl-Toeglhofer, AM Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Int J Mol Sci. 2023; 24(7): Doi: 10.3390/ijms24076184 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2022

Erfinanda, L; Zou, L; Gutbier, B; Kneller, L; Weidenfeld, S; Michalick, L; Lei, D; Reppe, K; Teixeira, Alves, LG; Schneider, B; Zhang, Q; Li, C; Fatykhova, D; Schneider, P; Liedtke, W; Sohara, E; Mitchell, TJ; Gruber, AD; Hocke, A; Hippenstiel, S; Suttorp, N; Olschewski, A; Mall, MA; Witzenrath, M; Kuebler, WM Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiation.
Sci Transl Med. 2022; 14(674): eabg8577 Doi: 10.1126/scitranslmed.abg8577
Web of Science PubMed FullText FullText_MUG

 

2021

Waldherr, L; Seitanidou, M; Jakesova, M; Handl, V; Honeder, S; Nowakowska, M; Tomin, T; Rad, MK; Schmidt, T; Distl, J; Birner-Gruenberger, R; Campe, G; Schafer, U; Berggren, M; Rinner, B; Asslaber, M; Ghaffari-Tabrizi-Wizsy, N; Patz, S; Simon, DT; Schindl, R Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
ADV MATER TECHNOL-US. 2021; 2001302 Doi: 10.1002/admt.202001302 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2020

Elbelt, U; Schlaffer, SM; Buchfelder, M; Knappe, UJ; Vila, G; Micko, A; Deutschbein, T; Unger, N; Lammert, A; Topuzoglu-Müller, T; Bojunga, J; Droste, M; Johanssen, S; Kolenda, H; Ritzel, K; Buslei, R; Strasburger, CJ; Petersenn, S; Honegger, J Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomas-A German Survey.
J Clin Endocrinol Metab. 2020; 105(3): Doi: 10.1210/clinem/dgz211
Web of Science PubMed FullText FullText_MUG

 

2019

Darlix, A; Mandonnet, E; Freyschlag, CF; Pinggera, D; Forster, MT; Voss, M; Steinbach, J; Loughrey, C; Goodden, J; Banna, G; Di Blasi, C; Foroglou, N; Hottinger, AF; Baron, MH; Pallud, J; Duffau, H; Rutten, GJ; Almairac, F; Fontaine, D; Taillandier, L; Pessanha Viegas, C; Albuquerque, L; von Campe, G; Urbanic-Purkart, T; Blonski, M Chemotherapy and diffuse low-grade gliomas: a survey within the European Low-Grade Glioma Network.
NEURO-ONCOL PRACT. 2019; 6(4): 264-273. Doi: 10.1093/nop/npy051 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Micko, ASG; Höftberger, R; Wöhrer, A; Millesi, M; Knosp, E; Wolfsberger, S MGMT assessment in pituitary adenomas: comparison of different immunohistochemistry fixation chemicals.
Pituitary. 2018; 21(3):266-273 Doi: 10.1007/s11102-018-0862-x [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2017

Likar, R; Nahler, G The use of cannabis in supportive care and treatment of brain tumor.
Neurooncol Pract. 2017; 4(3): 151-160. Doi: 10.1093/nop/npw027 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Mandonnet, E; Wager, M; Almairac, F; Baron, MH; Blonski, M; Freyschlag, CF; Barone, F; Fontaine, D; Pallud, J; Hegi, M; Viegas, C; Zetterling, M; Spena, G; Goodden, J; Rutten, GJ; Taillandier, L; Foroglu, N; Darlix, A; Skrap, M; Martino, J; von Campe, G; Madadaki, C; Gayat, E; de Witt Hamer, P; Gil Robles, S; Sarubbo, S; Santarius, T; Bello, L; Forster, MT; Duffau, H Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?
Neurooncol Pract. 2017; 4(4):241-247 Doi: 10.1093/nop/npw031 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Micko, ASG; Wöhrer, A; Höftberger, R; Vila, G; Marosi, C; Knosp, E; Wolfsberger, S MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas.
Pituitary. 2017; 20(6):643-653 Doi: 10.1007/s11102-017-0829-3 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2016

Brunner, TB The rationale of combined radiotherapy and chemotherapy - Joint action of Castor and Pollux.
Best Pract Res Clin Gastroenterol. 2016; 30(4):515-28 Doi: 10.1016/j.bpg.2016.07.002
Web of Science PubMed FullText FullText_MUG

 

2015

Hoffermann, M; Bruckmann, L; Kariem Mahdy, A; Asslaber, M; Payer, F; von Campe, G Treatment results and outcome in elderly patients with glioblastoma multiforme--a retrospective single institution analysis.
Clin Neurol Neurosurg. 2015; 128(2):60-69 Doi: 10.1016/j.clineuro.2014.11.006
Web of Science PubMed FullText FullText_MUG

 

2013

Grah, JJ; Katalinic, D; Stern-Padovan, R; Paladino, J; Santek, F; Juretic, A; Zarkovic, K; Plestina, S; Supe, M Leptomeningeal and intramedullary metastases of glioblastoma multiforme in a patient reoperated during adjuvant radiochemotherapy.
World J Surg Oncol. 2013; 11(1):55-55 Doi: 10.1186/1477-7819-11-55 (- Case Report) [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2012

Langsenlehner, T; Groll, MJ; Quehenberger, F; Payer, F; Mokry, M; Kapp, KS Interdisciplinary treatment of glioblastoma: analysis of prognostic factors and treatment results in unselected patients.
Neoplasma. 2012; 59(6):662-668 Doi: 10.4149/neo_2012_084 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2011

Faoro, D; von Bueren, AO; Shalaby, T; Sciuscio, D; Hürlimann, ML; Arnold, L; Gerber, NU; Haybaeck, J; Mittelbronn, M; Rutkowski, S; Hegi, M; Grotzer, MA Expression of O⁶-methylguanine-DNA methyltransferase in childhood medulloblastoma.
J Neurooncol. 2011; 103(1):59-69 Doi: 10.1007/s11060-010-0366-7 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Widhalm, G; Wolfsberger, S; Preusser, M; Woehrer, A; Kotter, MR; Czech, T; Marosi, C; Knosp, E O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
Cancer. 2009; 115(5):1070-80 Doi: 10.1002/cncr.24053
Web of Science PubMed FullText FullText_MUG

 

2008

Spieth, K; Kaufmann, R; Dummer, R; Garbe, C; Becker, JC; Hauschild, A; Tilgen, W; Ugurel, S; Beyeler, M; Bröcker, EB; Kaehler, KC; Pföhler, C; Gille, J; Leiter, U; Schadendorf, D Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Ann Oncol. 2008; 19(4):801-806 Doi: 10.1093/annonc/mdm565 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2006

Hassler, M; Micksche, M; Stockhammer, G; Pichler, J; Payer, F; Abuja, B; Deinsberger, R; Marosi, C Temozolomide for recurrent or progressive high-grade malignant glioma: results of an Austrian multicenter observational study.
Wien Klin Wochenschr. 2006; 118(7-8):230-238 Doi: 10.1007/s00508-006-0576-3
Web of Science PubMed FullText FullText_MUG

 

Schadendorf, D; Hauschild, A; Ugurel, S; Thoelke, A; Egberts, F; Kreissig, M; Linse, R; Trefzer, U; Vogt, T; Tilgen, W; Mohr, P; Garbe, C Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study.
Ann Oncol. 2006; 17(10):1592-1597 Doi: 10.1093/annonc/mdl148 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

2005

Kaufmann, R; Spieth, K; Leiter, U; Mauch, C; von den Driesch, P; Vogt, T; Linse, R; Tilgen, W; Schadendorf, D; Becker, JC; Sebastian, G; Krengel, S; Kretschmer, L; Garbe, C; Dummer, R Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
J Clin Oncol. 2005; 23(35):9001-9007 Doi: 10.1200/JCO.2005.01.1551 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Richtig, E; Ludwig, R; Kerl, H; Smolle, J Organ- and treatment-specific local response rates to systemic and local treatment modalities in stage IV melanoma.
BRIT J DERMATOL. 2005; 153(5): 925-931. Doi: 10.1111/j.1365-2133.2005.06796.x
Web of Science PubMed FullText FullText_MUG

 

2004

Richtig, E; Hofmann-Wellenhof, R; Pehamberger, H; Forstinger, Ch; Wolff, K; Mischer, P; Raml, J; Fritsch, P; Zelger, B; Ratzinger, G; Koller, J; Lang, A; Konrad, K; Kindermann-Glebowski, E; Seeber, A; Steiner, A; Fialla, R; Pachinger, W; Kos, C; Klein, G; Kehrer, H; Kerl, H; Ulmer, H; Smolle, J Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
BRIT J DERMATOL. 2004; 151(1): 91-98. Doi: 10.1111/j.1365-2133.2004.06019.x
Web of Science PubMed FullText FullText_MUG

 

2000

Reinhold, U; Ugurel, S; Tilgen, W; Kadiata, MM; Olivares, E; Nadi, AB; Malaisse, WJ Antitumoral action of 2-deoxy-D-glucose tetraacetate in human melanoma cells.
Oncol Rep. 2000; 7(5):1093-1097 Doi: 10.3892/or.7.5.1093
Web of Science PubMed FullText FullText_MUG Google Scholar

 

↑ Seitenanfang / Navigation

© Med Uni Graz • Impressum